Metoject pens replace prefilled syringes

Medac has launched Metoject PEN (methotrexate) a single-use prefilled pen for subcutaneous injection, to replace the existing syringe presentation.

Metoject is no longer indicated for Crohn's disease.
Metoject is no longer indicated for Crohn's disease.

The new prefilled pen device is available in the full range of existing doses and has the same colour coding as the syringe to distinguish between the different strengths.

It is indicated for the treatment of:

  • severe recalcitrant disabling psoriasis
  • severe psoriatic arthritis
  • polyarthritic forms of severe active juvenile idiopathic arthritis when the response to NSAIDs has been inadequate
  • active rheumatoid arthritis.

The Metoject pen device is not currently licensed for use in Crohn's disease.

View Metoject drug record

Further information: Medac

Follow MIMS on Twitter

Sign up for MIMS bulletins


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.